Expert opinion on ADT for CRPC today

As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used to.

In the meantime, the appropriate use of ADT in the management of men with castration-resistant prostate cancer CRPC) is a much discussed topic. A new article on the Medscape Oncology web site from Mary-Ellen Taplin, MD (“Secondary hormone therapy for castration-resistant prostate cancer“) offers her expert opinion on this issue that will be of interest to some of our readers with progressive and high-risk disease.

As usual, to be able to access the Medscape web sites, you do have to register to become a members, but you can avoid receiving too many bothersome e-mails without a lot of effort, and access to Medscape is free (but you do have to put up with the advertising).

One Response

  1. In case anyone is considering at trip to Dana Farber, it is my personal opinion that Dr. Taplin is a terrific clinical doctor. I visited with her several years ago.

    Bill Manning

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: